Hub71+ Life Sciences — Cohort 20
Hub71+ Life Sciences is the health / biotech / medtech vertical for Cohort 20, open as of 23 August 2026 with no verified close date. Abu Dhabi has been buying this category in public. You need more than a wellness app — regulators, hospitals, or wet work. Same Access-class substance rules. Same permanent slug for future cohorts.
DESK TAKE
Only if life sciences is the company. A fitness tracker with a doctor on the advisory board is Access, not this row.
ELIGIBILITY
Hub71's specialist track for life sciences startups from pre-seed to Series A that want to build and scale from Abu Dhabi. - Open to startups in biotechnology, MedTech and digital health, from precision medicine to biomanufacturing - Pre-seed to Series A stage companies - At least one founder must commit to relocating long-term and building a team in Abu Dhabi - Application requires a pitch deck (PDF) covering problem, solution, value proposition, business model, competition, market, traction, funds raised and founding team - Four-round selection process, including pitch sessions with Hub71 ecosystem partners
QUESTIONS
Do they help with DOH / DHA?
The value is the Abu Dhabi health stack and partners. Confirm on the current brief; we do not speak for Hub71.
Is there a separate grant?
Incentives live in the Hub71 / ADGM / ADIO stack. This page is the intake, not a named cheque size.